Therapeutic area intelligence for Immune Thrombocytopenia with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Novartis →

Assets

ianalumab →

Mezagitamab →

Recent signals(2)

ClinicalJuly 31, 2026

Mezagitamab Study Initiated for Chronic Primary Immune Thrombocytopenia

A clinical trial is underway to evaluate the efficacy of mezagitamab in stabilizing platelet counts in adults with chronic primary immune thrombocytopenia compared to placebo.

ClinicalJuly 11, 2026

Novartis initiates tolerability study of ianalumab with TPO-RA in ITP patients

A new study is assessing the tolerability of ianalumab combined with investigator's choice TPO-RA in ITP patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.